TY - JOUR
T1 - Efficient human-like antibody repertoire and hybridoma production in trans-chromosomic mice carrying megabase-sized human immunoglobulin loci
AU - Satofuka, Hiroyuki
AU - Abe, Satoshi
AU - Moriwaki, Takashi
AU - Okada, Akane
AU - Kazuki, Kanako
AU - Tanaka, Hiroshi
AU - Yamazaki, Kyotaro
AU - Hichiwa, Genki
AU - Morimoto, Kayoko
AU - Takayama, Haruka
AU - Nakayama, Yuji
AU - Hatano, Shinya
AU - Yada, Yutaro
AU - Murakami, Yasufumi
AU - Baba, Yoshihiro
AU - Oshimura, Mitsuo
AU - Tomizuka, Kazuma
AU - Kazuki, Yasuhiro
N1 - Funding Information:
We thank Y. Sato (DNA Chip Research Inc.) for assistance with generating Circos plots, frequency analyses of VH and VK, and circular dendrograms. We thank Dr. S. Aizawa at RIKEN for providing TT2F cell line. We thank Y. Sumida, E. Kaneda, K. Yoshida, M. Fukino, A. Ashiba, Dr. K. Nakamura, T. Kurosaki, F. Adachi, Y. Wang and R. Ohnishi at Tottori University and S. Takehara at Trans Chromosomics Inc. for assistance with generating and maintaining TC-mAb mice, and M. Takami, M. Tanaka, K. Hiramatsu, K. Honma, I. Kanazawa and T. Endo at Trans Chromosomics Inc., Y. Nagashima, and M. Morimura at Tottori University and Y. Okabe at Order-made Medical Research, Inc. for assistance with human Ab production and establishing antigen-specific hybridoma cell lines. We also thank Dr. H. Kugoh, Dr. M. Hiratsuka, Dr. T. Ohbayashi, Dr. F. Okada, Dr. M. Osaki and Dr. T. Ohira at Tottori University and Dr. X. Gao at Harbin Medical University for critical discussions. This study was supported in part by JSPS KAKENHI Grant Number JP21K18256 (Y.B.), the Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS) from the Japan Agency for Medical Research and Development (AMED) under Grant Number JP21am0101124 (Y.K.), the Science and Technology Platform Program for Advanced Biological Medicine from AMED under Grant Number JP21am0401002 (Y.K. and K.T.), the Basic Science and Platform Technology Program for Innovative Biological Medicine from AMED under Grant Number JP18am0301009 (Y.K.), AMED under Grant Number JP21fk0108141 (Y.K.), AMED under Grant Number JP21gm1610006 (Y.K. and K.T.), and JST CREST Grant Number JPMJCR18S4, Japan (Y.K. and K.T.). This research was partly performed at the Tottori Bio Frontier managed by Tottori prefecture. We thank Jeremy Allen, PhD, and Mitchell Arico from Edanz ( https://jp.edanz.com/ac ) for editing a draft of this manuscript.
Funding Information:
We thank Y. Sato (DNA Chip Research Inc.) for assistance with generating Circos plots, frequency analyses of VH and VK, and circular dendrograms. We thank Dr. S. Aizawa at RIKEN for providing TT2F cell line. We thank Y. Sumida, E. Kaneda, K. Yoshida, M. Fukino, A. Ashiba, Dr. K. Nakamura, T. Kurosaki, F. Adachi, Y. Wang and R. Ohnishi at Tottori University and S. Takehara at Trans Chromosomics Inc. for assistance with generating and maintaining TC-mAb mice, and M. Takami, M. Tanaka, K. Hiramatsu, K. Honma, I. Kanazawa and T. Endo at Trans Chromosomics Inc., Y. Nagashima, and M. Morimura at Tottori University and Y. Okabe at Order-made Medical Research, Inc. for assistance with human Ab production and establishing antigen-specific hybridoma cell lines. We also thank Dr. H. Kugoh, Dr. M. Hiratsuka, Dr. T. Ohbayashi, Dr. F. Okada, Dr. M. Osaki and Dr. T. Ohira at Tottori University and Dr. X. Gao at Harbin Medical University for critical discussions. This study was supported in part by JSPS KAKENHI Grant Number JP21K18256 (Y.B.), the Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS) from the Japan Agency for Medical Research and Development (AMED) under Grant Number JP21am0101124 (Y.K.), the Science and Technology Platform Program for Advanced Biological Medicine from AMED under Grant Number JP21am0401002 (Y.K. and K.T.), the Basic Science and Platform Technology Program for Innovative Biological Medicine from AMED under Grant Number JP18am0301009 (Y.K.), AMED under Grant Number JP21fk0108141 (Y.K.), AMED under Grant Number JP21gm1610006 (Y.K. and K.T.), and JST CREST Grant Number JPMJCR18S4, Japan (Y.K. and K.T.). This research was partly performed at the Tottori Bio Frontier managed by Tottori prefecture. We thank Jeremy Allen, PhD, and Mitchell Arico from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Trans-chromosomic (Tc) mice carrying mini-chromosomes with megabase-sized human immunoglobulin (Ig) loci have contributed to the development of fully human therapeutic monoclonal antibodies, but mitotic instability of human mini-chromosomes in mice may limit the efficiency of hybridoma production. Here, we establish human antibody-producing Tc mice (TC-mAb mice) that stably maintain a mouse-derived, engineered chromosome containing the entire human Ig heavy and kappa chain loci in a mouse Ig-knockout background. Comprehensive, high-throughput DNA sequencing shows that the human Ig repertoire, including variable gene usage, is well recapitulated in TC-mAb mice. Despite slightly altered B cell development and a delayed immune response, TC-mAb mice have more subsets of antigen-specific plasmablast and plasma cells than wild-type mice, leading to efficient hybridoma production. Our results thus suggest that TC-mAb mice offer a valuable platform for obtaining fully human therapeutic antibodies, and a useful model for elucidating the regulation of human Ig repertoire formation.
AB - Trans-chromosomic (Tc) mice carrying mini-chromosomes with megabase-sized human immunoglobulin (Ig) loci have contributed to the development of fully human therapeutic monoclonal antibodies, but mitotic instability of human mini-chromosomes in mice may limit the efficiency of hybridoma production. Here, we establish human antibody-producing Tc mice (TC-mAb mice) that stably maintain a mouse-derived, engineered chromosome containing the entire human Ig heavy and kappa chain loci in a mouse Ig-knockout background. Comprehensive, high-throughput DNA sequencing shows that the human Ig repertoire, including variable gene usage, is well recapitulated in TC-mAb mice. Despite slightly altered B cell development and a delayed immune response, TC-mAb mice have more subsets of antigen-specific plasmablast and plasma cells than wild-type mice, leading to efficient hybridoma production. Our results thus suggest that TC-mAb mice offer a valuable platform for obtaining fully human therapeutic antibodies, and a useful model for elucidating the regulation of human Ig repertoire formation.
UR - http://www.scopus.com/inward/record.url?scp=85127669424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127669424&partnerID=8YFLogxK
U2 - 10.1038/s41467-022-29421-2
DO - 10.1038/s41467-022-29421-2
M3 - Article
C2 - 35383174
AN - SCOPUS:85127669424
SN - 2041-1723
VL - 13
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 1841
ER -